Carol Devine Miller
Price Movement Since Trade
How each stock has moved from the trade date to the most recent close.
Suspicious Timing Detected
5 flagsRep. Carol Devine Miller sold $1,001 - $15,000 in $UPS on March 10, 2025 — 30 days before the "Protecting Employees and Retirees in Business Bankruptcies Act of 2025" (S. 1381) was introduced, a bill with potential bearish implications for corporations.
Rep. Carol Devine Miller bought $1,001 - $15,000 in $GILD on March 10, 2025 — 17 days before the "Providing Veterans Essential Medications Act" (HR1970) was introduced, a bill potentially beneficial for pharmaceutical companies.
Rep. Carol Devine Miller bought $1,001 - $15,000 in $LMT on March 10, 2025 — 22 days before the "Taiwan Allies Fund Act" (HR2559) was introduced, a bill potentially beneficial for defense contractors.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | $AFL | AFLAC Incorporated Common Stock (AFL) [ST] | $1K-$15K | $106.76 | $114.62 | +7.4% | Mar 10, 2025 |
| BUY | $AWK | American Water Works Company, Inc. Common Stock (AWK) [ST] | $1K-$15K | — | — | — | Mar 10, 2025 |
| BUY | $CME | CME Group Inc. - Class A Common Stock (CME) [ST] | $1K-$15K | $262.28 | — | — | Mar 10, 2025 |
| BUY | $GILD | Gilead Sciences, Inc. - Common Stock (GILD) [ST] | $1K-$15K | $117.21 | — | — | Mar 10, 2025 |
| BUY | $HON | Honeywell International Inc. - Common Stock (HON) [ST] | $1K-$15K | $213.82 | — | — | Mar 10, 2025 |
| BUY | $ITW | Illinois Tool Works Inc. Common Stock (ITW) [ST] | $1K-$15K | $267.67 | $269.29 | +0.6% | Mar 10, 2025 |
| BUY | $LMT | Lockheed Martin Corporation Common Stock (LMT) [ST] | $1K-$15K | $479.17 | — | — | Mar 10, 2025 |
| BUY | $PEP | PepsiCo, Inc. - Common Stock (PEP) [ST] | $1K-$15K | $156.25 | — | — | Mar 10, 2025 |
| BUY | $HSY | The Hershey Company Common Stock (HSY) [ST] | $1K-$15K | $186.36 | — | — | Mar 10, 2025 |
| SELL | $PFE | Pfizer, Inc. Common Stock (PFE) [ST] | $1K-$15K | $26.64 | — | — | Mar 10, 2025 |
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
Taiwan Allies Fund Act
The Taiwan Allies Fund Act (HR2559) is an early-stage authorization bill with $0 funding that has been stalled in the House Foreign Affairs Committee for over a year with no legislative action. It carries zero near-term market impact for any traded security, including TSM, which remains driven by semiconductor fundamentals and real appropriations bills like the CHIPS Act.
Customs Facilitation Act of 2025
The Customs Facilitation Act of 2025 (S.956) mandates a uniform automated cargo processing platform and continuous ACE modernization. It is a structural efficiency gain for logistics intermediaries like $CHRW and $JBHT, reducing customs friction and improving asset turns. $ORCL is positioned to bid on the IT modernization contracts that follow. At $186.2 and $245.89 respectively, $CHRW and $JBHT have already priced in 12-16% gains over 30 days. The bill is early-stage (referred to Senate Finance), so the market reaction reflects the long-term structural thesis, not imminent passage.
Sarah Katz Caffeine Safety Act
The Sarah Katz Caffeine Safety Act (HR2511) imposes new caffeine labeling and menu disclosure requirements on beverage manufacturers and restaurant chains. The bill is in early committee stage with no markup scheduled—near-term market impact is minimal. Pure-play energy drink company $MNST faces the highest relative compliance cost burden, while $SBUX faces menu redesign costs. Diversified giants $KO and $PEP have negligible relative impact.
SCREENS for Cancer Act of 2025
The SCREENS for Cancer Act reauthorizes and expands national cancer screening programs for 2026-2030. This creates a structural volume tailwind for Labcorp ($LH) and Quest Diagnostics ($DGX) as the primary processors of screening lab work. Both stocks have been down over the past month on broader market weakness, not bill-specific news — the authorization provides a real federal program pipeline for incremental testing revenue once appropriations are secured.
Ellie’s Law
Ellie's Law (HR2678) is an early-stage authorization bill directing NINDS to research unruptured intracranial aneurysms. It authorizes zero dollars, has no funding appropriation, and has only been referred to committee. Market impact is negligible in the near term for device and research tool providers like MDT, TMO, ILMN, and DGX, as no actual spending exists and the legislative path is years from completion.
Providing Veterans Essential Medications Act
HR1970 (Providing Veterans Essential Medications Act) is in early legislative stages, having been referred to the House Veterans' Affairs subcommittee. The bill mandates VA reimbursement for high-cost medications dispensed to veterans in State nursing homes, but authorizes no specific funding and remains months from passage. Real market data shows CVS up 16% in 30 days while CAH is down 10%, reflecting broader distribution-sector dynamics rather than this early-stage bill.
ROCR Value Based Program Act
S.1031 (ROCR Value Based Program Act) is an early-stage bill proposing a shift to bundled Medicare payments for radiation oncology. It presents a structural long-term bearish signal for equipment vendors like GE HealthCare ($GEHC) but has no near-term market impact due to its early legislative stage and absence of funding. $GEHC is already down 16% in 30 days, trading at $59.66 near its 52-week low of $58.75.
Protecting Life and Integrity in Research Act of 2025
HR2075 is an early-stage House bill that would ban federal funding for research using human fetal tissue from induced abortions. It is stuck in committee with no floor action since introduction in March 2025. The market data shows a broad 30-day decline across biomedical stocks, but $TMO and $DHR have moved -1.19% and +0.72% respectively in the past 7 days — not signaling acute legislative risk. The bill has zero direct appropriations and remains a low-probability risk factor for life sciences tool suppliers.
To prohibit the issuance of licenses for the exportation of certain defense articles to the United Arab Emirates, and for other purposes.
HR2059 directly prohibits defense article exports to the UAE until it certifies cessation of support for the Rapid Support Forces in Sudan. This bill blocks multi-billion dollar F-35 (Lockheed), F-15 (Boeing), Patriot (RTX), and armored vehicle (General Dynamics) sales to a top-tier Middle East customer. The defense sector faces a direct revenue headwind, with Lockheed Martin most exposed given its $512 level and 7-day decline of -7.77%.
Aviation Funding Stability Act of 2025
The Aviation Funding Stability Act (S.1045) is a procedural bill in early committee stage (referred to Finance, not yet passed) that would guarantee FAA funding from the Airport and Airway Trust Fund during government shutdowns. For $BA, $LMT, and $RTX, this removes a discrete operational risk to FAA-dependent programs, but near-term market impact is low given the bill's early legislative stage. Market data shows all three stocks under pressure in the past 30 days: $BA down 2.4% in the past week despite a +14% monthly gain, $LMT down 15.6% monthly, and $RTX down 9.6% monthly.
Other Filings by Carol Devine Miller
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.